Algeta ASA is considering establishing a third leg to its biopharmaceutical business by possibly in-licensing targeted therapies for cancer. This emerged during a briefing by the Norwegian company for analysts, which was called to discuss the commercialisation of Xofigo, the company’s lead asset. Xofigo is a radiopharmaceutical for men with prostate cancer that has spread to the bone.
